Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Human papillomavirus vaccination: current indications and future directions.

Gattoc L, Nair N, Ault K.

Obstet Gynecol Clin North Am. 2013 Jun;40(2):177-97. doi: 10.1016/j.ogc.2013.03.007.

2.

Cancers attributable to human papillomavirus infection.

Grulich AE, Jin F, Conway EL, Stein AN, Hocking J.

Sex Health. 2010 Sep;7(3):244-52. doi: 10.1071/SH10020.

PMID:
20719211
3.

Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.

Serrano B, de Sanjosé S, Tous S, Quiros B, Muñoz N, Bosch X, Alemany L.

Eur J Cancer. 2015 Sep;51(13):1732-41. doi: 10.1016/j.ejca.2015.06.001.

PMID:
26121913
4.

Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.

Muñoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan JT, Lupinacci LC, Giacoletti KE, Sings HL, James MK, Hesley TM, Barr E, Haupt RM.

J Natl Cancer Inst. 2010 Mar 3;102(5):325-39. doi: 10.1093/jnci/djp534.

5.

A review of clinical trials of human papillomavirus prophylactic vaccines.

Schiller JT, Castellsagué X, Garland SM.

Vaccine. 2012 Nov 20;30 Suppl 5:F123-38. doi: 10.1016/j.vaccine.2012.04.108. Review.

6.

[Prevention of HPV-associated neoplasias by vaccination - short version of the German S3 (level 3) guideline].

Gross G, Gissmann L, Hillemanns P, Ikenberg H, Kaufmann AM, Petry KU, Pfister H, Schneede P, Schneider A, Smola S; für das HPV-Management Forum..

Dtsch Med Wochenschr. 2010 May;135(21):1083-6. doi: 10.1055/s-0030-1253704. German. No abstract available.

PMID:
20486060
7.

Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis.

Van de Velde N, Boily MC, Drolet M, Franco EL, Mayrand MH, Kliewer EV, Coutlée F, Laprise JF, Malagón T, Brisson M.

J Natl Cancer Inst. 2012 Nov 21;104(22):1712-23. doi: 10.1093/jnci/djs395.

8.

Monitoring the control of human papillomavirus (HPV) infection and related diseases in Australia: towards a national HPV surveillance strategy.

Brotherton JM, Kaldor JM, Garland SM.

Sex Health. 2010 Sep;7(3):310-9. doi: 10.1071/SH09137.

PMID:
20719220
9.

Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.

Nygård M, Hansen BT, Dillner J, Munk C, Oddsson K, Tryggvadottir L, Hortlund M, Liaw KL, Dasbach EJ, Kjær SK.

PLoS One. 2014 Feb 5;9(2):e88323. doi: 10.1371/journal.pone.0088323.

10.

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe.

Marty R, Roze S, Bresse X, Largeron N, Smith-Palmer J.

BMC Cancer. 2013 Jan 8;13:10. doi: 10.1186/1471-2407-13-10.

11.

[The disease burden of human papillomavirus in men is substantial and can potentially be prevented].

Kiellberg Larsen H, Kofoed K, Sand C.

Ugeskr Laeger. 2013 Feb 4;175(6):349-53. Review. Danish.

PMID:
23402241
12.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012..

Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001. Review.

PMID:
24331745
13.

Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.

Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.

Vaccine. 2013 Aug 20;31(37):3922-7. doi: 10.1016/j.vaccine.2013.06.044.

PMID:
23806241
14.

Human papillomavirus vaccine trials and tribulations: Clinical perspectives.

Handler MZ, Handler NS, Majewski S, Schwartz RA.

J Am Acad Dermatol. 2015 Nov;73(5):743-56; quiz 757-8. doi: 10.1016/j.jaad.2015.05.040. Review.

PMID:
26475534
15.

Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.

Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, Cronin KA, Watson M, Schiffman M, Henley SJ, Schymura MJ, Anderson RN, Yankey D, Edwards BK.

J Natl Cancer Inst. 2013 Feb 6;105(3):175-201. doi: 10.1093/jnci/djs491.

16.

Knowledge of human papillomavirus (HPV) and the HPV vaccine in a national sample of Australian men and women.

Pitts MK, Heywood W, Ryall R, Smith AM, Shelley JM, Richters J, Simpson JM.

Sex Health. 2010 Sep;7(3):299-303. doi: 10.1071/SH09150.

PMID:
20719218
17.

[AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].

Malinova M.

Akush Ginekol (Sofiia). 2015;54 Suppl 1:25-31. Bulgarian.

PMID:
26137767
18.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012..

Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. Review.

19.

Global burden of human papillomavirus and related diseases.

Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, Vignat J, Ferlay J, Bray F, Plummer M, Franceschi S.

Vaccine. 2012 Nov 20;30 Suppl 5:F12-23. doi: 10.1016/j.vaccine.2012.07.055. Review.

PMID:
23199955
20.

[The first vaccine against cancer: the human papillomavirus vaccine].

Bősze P.

Orv Hetil. 2013 Apr 21;154(16):603-18. doi: 10.1556/OH.2013.29593. Hungarian.

PMID:
23587540
Items per page

Supplemental Content

Support Center